Perioperative durvalumab with chemotherapy for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery can improve outcomes for people with muscle-invasive bladder cancer. It aims to see if this combination is more effective than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with muscle-invasive bladder cancer that has not spread beyond the bladder or to nearby lymph nodes in a way that makes it inoperable.
- You are planning to have surgery to remove your bladder (radical cystectomy).
- You have not had chemotherapy or immunotherapy for your muscle-invasive bladder cancer before.
- You are physically active enough to manage daily tasks (ECOG performance status 0 or 1).
- You have a life expectancy of at least 12 weeks from starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (disitamab vedotin) and an immunotherapy (toripalimab) before surgery for bladder cancer that has grown into the muscle. The goal is to see if this combination works better than the standard chemotherapy plus immunotherapy approach.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
This early-phase trial tests durvalumab given with an experimental bladder cancer vaccine to help stop or slow high-risk bladder cancer that did not respond to or cannot be treated with BCG. It also evaluates safety and how well the treatment works in this setting.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.